MGD024 in Relapsed or Refractory Hematologic Malignancies

Phase 1, open-label, single-arm trial of MGD-024 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), classical Hodgkin lymphoma (cHL) and 5 more, sponsored by MacroGenics. Primary endpoints: Number of severe side effects at 28 days and Number and types of adverse events (AEs), including serious adverse events (SAEs), and AEs leading to treatment discontinuation at 12 months. Started Jul 2022; status: active, not recruiting.